Enanta Pharmaceuticals (Enanta Pharmaceuticals) Cash-to-Debt

: 13.23 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Enanta Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 13.23.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Enanta Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Enanta Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ENTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.5 Med: 372.05 Max: No Debt
Current: 13.23

During the past 13 years, Enanta Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 7.50. And the median was 372.05.

ENTA's Cash-to-Debt is ranked better than
59.65% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs ENTA: 13.23

Enanta Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Enanta Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Enanta Pharmaceuticals Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

Get a 7-Day Free Trial

1,676.18

47.74

45.79

9.87

13.95

Enanta Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															8.46	7.50	13.96	13.95	13.23

Competitive Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enanta Pharmaceuticals Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cash-to-Debt falls into.

Enanta Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Enanta Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	369.91	/	(5.275	+	21.238)
	=	13.95

Enanta Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	337.151	/	(4.966	+	20.524)
	=	13.23

Enanta Pharmaceuticals (NAS:ENTA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Enanta Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals (Enanta Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

9EP:Germany

Address

500 Arsenal Street, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Executives

Terry Vance	director	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Scott T. Rottinghaus	officer: Chief Medical Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu	officer: Sr. VP, Business Dev.	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer	officer: Sr. VP, New Product Dev.	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or	officer: Chief Scientific Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Jay R. Luly	director, officer: President and CEO	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner	director	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett	officer: Treasurer and CFO	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda	officer: Sr. VP & Chief Medical Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Yujiro S Hata	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta	director	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901